Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ZAP70 | P43403 | 7/20 | 0.58 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.55 |
| ▸ | ULK1 | O75385 | 2/20 | 0.52 |
| ▸ | AXL | P30530 | 5/20 | 0.49 |
| ▸ | NEK2 | P51955 | 1/20 | 0.49 |
| ▸ | CDK7 | P50613 | 1/20 | 0.49 |
| ▸ | CDK9 | P50750 | 1/20 | 0.49 |
| ▸ | IGF1R | P08069 | 1/20 | 0.48 |
| ▸ | AURKA | O14965 | 1/20 | 0.47 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.47 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.45 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.44 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.44 |
| ▸ | CDK1 | P06493 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12311717 | 0.85 | ZAP70 (0.70) | ZAP70ALKULK1AXLNEK2 | |
| SCHEMBL25056256 | 0.84 | ZAP70 (0.48) | ZAP70ALKULK1AXLNEK2 | |
| SCHEMBL13849392 | 0.81 | ZAP70 (0.57) | ZAP70ALKULK1AXLCDK7 | |
| SCHEMBL12780617 | 0.80 | ZAP70 (0.68) | ZAP70ALKULK1AXLIGF1R | |
| SCHEMBL12781900 | 0.80 | ZAP70 (0.61) | ZAP70ALKULK1AXLIGF1R | |
| SCHEMBL4088361 | 0.73 | ULK1 (0.72) | ZAP70ALKULK1AXLNEK2 | |
| SCHEMBL12312367 | 0.73 | ULK1 (0.81) | ZAP70ALKULK1NEK2CDK7 | |
| SCHEMBL12311812 | 0.73 | MAPK8 (0.61) | ALKULK1CDK7CDK9IGF1R | |
| SCHEMBL19225455 | 0.73 | AXL (0.45) | ZAP70ALKAXLNEK2CDK7 | |
| SCHEMBL2061451 | 0.72 | AXL (0.59) | ALKAXLNEK2CDK7CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131436-A1 | Pyrimidine Derivatives | NOVARTIS AG (CH) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131436-A1 | Pyrimidine Derivatives | DPYD, TYMP, TYMS | ZAP70 1678/4885ALK 2060/4885ULK1 1714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.